August 8th 2022
Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.
August 2nd 2022
A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.
July 21st 2022
Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.
July 13th 2022
Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.